Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biocept, Inc. stock logo
BIOC
Biocept
$0.97
$0.32
$27.00
$1.14M0.69764,067 shs751,400 shs
Centogene stock logo
CNTG
Centogene
$0.17
$0.25
$1.53
$8.80M-0.67150,868 shs8.36 million shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19171,879 shs4.12 million shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.05
-15.3%
$4.78
$0.53
$5.25
$40.78M-1.669,037 shs989 shs
Exagen Inc. stock logo
XGN
Exagen
$6.78
-4.1%
$6.78
$1.78
$7.95
$150.59M1.58142,900 shs134,662 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biocept, Inc. stock logo
BIOC
Biocept
0.00%0.00%0.00%0.00%0.00%
Centogene stock logo
CNTG
Centogene
0.00%0.00%0.00%0.00%-70.21%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%-6.88%-71.98%
OpGen, Inc. stock logo
OPGN
OpGen
0.00%-4.78%-3.24%+16.59%+49.38%
Exagen Inc. stock logo
XGN
Exagen
+1.14%+1.58%-0.70%+60.32%+266.32%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/AN/AN/AN/A
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
3.9654 of 5 stars
2.52.00.04.53.82.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biocept, Inc. stock logo
BIOC
Biocept
0.00
N/AN/AN/A
Centogene stock logo
CNTG
Centogene
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$7.5010.62% Upside

Current Analyst Ratings Breakdown

Latest CNTG, ENZ, XGN, BIOC, and OPGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Exagen Inc. stock logo
XGN
Exagen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/15/2025
Exagen Inc. stock logo
XGN
Exagen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
5/13/2025
Exagen Inc. stock logo
XGN
Exagen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/7/2025
Exagen Inc. stock logo
XGN
Exagen
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biocept, Inc. stock logo
BIOC
Biocept
$25.86M0.00N/AN/A$15.60 per share0.00
Centogene stock logo
CNTG
Centogene
$48.54M0.00N/AN/A($1.01) per share0.00
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M15.25N/AN/A($11.55) per share-0.35
Exagen Inc. stock logo
XGN
Exagen
$55.64M2.60N/AN/A$0.54 per share12.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biocept, Inc. stock logo
BIOC
Biocept
-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/A
Centogene stock logo
CNTG
Centogene
-$38.58MN/A0.00N/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%N/A
Exagen Inc. stock logo
XGN
Exagen
-$15.11M-$0.84N/AN/AN/A-27.34%-133.69%-34.87%8/4/2025 (Estimated)

Latest CNTG, ENZ, XGN, BIOC, and OPGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.18N/AN/AN/A$16.25 millionN/A
5/12/2025Q1 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biocept, Inc. stock logo
BIOC
Biocept
N/AN/AN/AN/AN/A
Centogene stock logo
CNTG
Centogene
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biocept, Inc. stock logo
BIOC
Biocept
2.88
1.81
1.70
Centogene stock logo
CNTG
Centogene
N/A
1.02
0.96
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
Exagen Inc. stock logo
XGN
Exagen
2.87
2.32
2.32

Institutional Ownership

CompanyInstitutional Ownership
Biocept, Inc. stock logo
BIOC
Biocept
N/A
Centogene stock logo
CNTG
Centogene
9.94%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Biocept, Inc. stock logo
BIOC
Biocept
1.61%
Centogene stock logo
CNTG
Centogene
1.93%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
Exagen Inc. stock logo
XGN
Exagen
12.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biocept, Inc. stock logo
BIOC
Biocept
502.63 million2.58 millionNot Optionable
Centogene stock logo
CNTG
Centogene
81027.08 millionN/ANot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
Exagen Inc. stock logo
XGN
Exagen
22021.30 million18.62 millionOptionable

Recent News About These Companies

Exagen Insider Ups Holding During Year
Exagen Inc. Prices Public Offering of Common Stock
Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biocept stock logo

Biocept NASDAQ:BIOC

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Centogene stock logo

Centogene NASDAQ:CNTG

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.05 -0.73 (-15.27%)
As of 12:53 PM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Exagen stock logo

Exagen NASDAQ:XGN

$6.78 -0.29 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$6.96 +0.19 (+2.73%)
As of 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.